转录本（上海）生物

Akston Biosciences is focused on developing therapeutics for diabetes.In May 2019, Akston Biosciences had signed a lease for an additional 14,000 square feet of space at the Cummings Center in Beverly, MA and started construction of a new GMP biologics manufacturing facility, a GMP quality control laboratory, and a large scale process development laboratory. The new capabilities would enable the production of GMP drug substance to support the clinical and commercial development.In April 2020, the company closed US $7.6 million Series E financing, including the conversion of US $2.5 million from notes sold previously.In May 2019, the company completed a $2.5 million convertible note financing.In May 2018, the company completed $3.9 million Series D financing, including the conversion of $1.9 million from Notes.In August 2016, the company completed $3.4 million series C financing round.In May 2015, Akston Biosciences completed its $1.6 million series B finan

转录本（上海）生物科技有限公司（RiboX Therapeutics）是一家由TOP跨国制药企业风险基金联合国内外知名风险投资机构投资孵化的初创企业，专注于发现和开发完全工程化的新一代RNA 疗法，研发中心位于张江。新一代RNA作为一种新型的RNA药物，可以克服当前mRNA 疗法的局限性，充分发挥RNA药物的潜力。

江苏茂行科技有限公司由基因编辑、免疫治疗领域知名专家和生物企业资深运营管理人士共同创立，致力于解决实体瘤的通用型CAR-T开发。 拥有独特的UCAR-T研发平台，可有效解决异体免疫细胞的移植物抗宿主病（GvHD）风险和排异问题（HvGR）。